A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis

NCT07719023 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

263

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis (IPF)

Interventions

DRUG: AK3280
DRUG: Placebo
DRUG: Pirfenidone

Sponsor

Shanghai Ark Biopharmaceutical Co., Ltd.